Powered by OpenAIRE graph
Found an issue? Give us feedback
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/ Australasian Journal...arrow_drop_down
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/
Australasian Journal of Dermatology
Article . 2025 . Peer-reviewed
License: CC BY
Data sources: Crossref
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/
PubMed Central
Article . 2025
License: CC BY
Data sources: PubMed Central
Australasian Journal of Dermatology
Article . 2025
Data sources: Europe PubMed Central
 View all 3 versions
Claim

Sycosis Barbae Treated With Bimekizumab

descriptionPublicationkeyboard_double_arrow_right Article 10 Oct 2025 English Publisher:WileyJournal:Australasian Journal of Dermatology, volume 66, pages 486-488 (issn: 0004-8380, eissn: 1440-0960, Copyright policy )
Authors: Matiar Madanchi; Riccardo Curatolo; Lorenzo S. Pelloni; Hazem A. Juratli;

doi: 10.1111/ajd.14608

pmid: 41074452

pmc: PMC12687684

Sycosis Barbae Treated With Bimekizumab

Abstract

ABSTRACT Sycosis barbae (SB) is a chronic, potentially scarring alopecia that primarily affects the beard. We report a unique case of refractory SB in a 31‐year‐old male successfully treated with bimekizumab, a dual inhibitor of interleukin (IL)‐17A and IL‐17F. Significant clinical improvement was observed after the second injection, with complete remission achieved after 4 months, highlighting the potential of this novel therapeutic approach for SB.

Related Organizations
Keywords

Male, Adult, Brief Report, Interleukin-17, Humans, Alopecia, Dermatologic Agents, Antibodies, Monoclonal, Humanized

  • BIP!
    Impact byBIP!
    selected citations
    These citations are derived from selected sources.
    This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
    		 0
    popularity
    This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.
    		 Average
    influence
    This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
    		 Average
    impulse
    This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.
    		 Average
Powered by OpenAIRE graph
Found an issue? Give us feedback
selected citations
These citations are derived from selected sources.
This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
BIP!Citations provided by BIP!
popularity
This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.
BIP!Popularity provided by BIP!
influence
This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
BIP!Influence provided by BIP!
impulse
This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.
BIP!Impulse provided by BIP!
0
Average
Average
Average
Green
hybrid